Longitudinal Trajectories of Weight Changes among People Living with HIV on Antiretroviral Therapy: A Group-Based Study

Xinsheng Wu,Lukun Zhang,Zhen Lu,Yuwei Li,Yun He,Fang Zhao,Qiaoli Peng,Xinyi Zhou,Hui Wang,Huachun Zou

DOI: https://doi.org/10.1016/j.isci.2023.108259

IF: 5.8

2023-01-01

iScience

Abstract:Weight changes vary among people living with HIV (PLHIV) on different antiretroviral therapy (ART) regimens. Here, we performed multi-trajectory modeling fitting growth mixture models (GMM) to identify longitudinal weight change trajectories of PLHIV. Multiple logistic regression was used to assess correlates of rapid weight gains; 12,683 PLHIV (median age: 34 years [interquartile range 29-42], 91.1% male) who initiated ART at the Third People's Hospital of Shenzhen, China, between January 2003 and September 2022 were included. We identified two trajectories: slow (70.5%) and rapid weight gains (29.5%). PLHIV who initiated ART with dolutegravir- (adjusted odds ratio [aOR] 2.46, 1.92-3.15), raltegravir- (2.74, 1.96-3.82), and lopinavir (1.62, 1.36-1.94)-based regimens were more likely to have rapid weight gains compared with efavirenz-based regimen. The monitoring of nutritional status should be strengthened for PLHIV who initiated these regimens during regular ART follow-ups.